Cipla is facing moderate headwinds at the moment. India business underwent a soft two quarters, US business faced supply issues in one main product and Trump tariff pressure has impacted the ...

Umang Vohra, Global CEO and MD of Cipla has warned the Indian pharmaceutical industry may have to gear up for the possibility of having distributive global manufacturing network in the next 5-10 ...

"Formosa Pharma welcomes this partnership with Cipla, a well-renowned and respected global pharmaceutical brand. We appreciate their recognition and desire to add APP13007 to their rich portfolio of ...